Ken Griffin Bio Line Rx Ltd. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 49,900 shares of BLRX stock, worth $31,936. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,900
Previous 24,100
107.05%
Holding current value
$31,936
Previous $26,000
7.69%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
4.29MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$1.25 Million0.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$522,0374.05% of portfolio
-
Envestnet Asset Management Inc214KShares$136,8530.0% of portfolio
-
Values First Advisors, Inc.204KShares$130,4050.07% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$79,0910.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $39.4M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...